In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

Shares of Silexion Therapeutics lost more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026.

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

Silexion Therapeutics Corp. announced promising preclinical results for its second-generation RNA interference therapy, SIL-204, which demonstrates synergistic efficacy when used in combination ...